{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:56:24Z","timestamp":1793048184785,"version":"4.5.0"},"reference-count":181,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Mesothelioma is a malignancy of serosal membranes including the peritoneum, pleura, pericardium and the tunica vaginalis of the testes. Malignant mesothelioma (MM) is a rare disease with a global incidence in countries like Italy of about 1.15 per 100,000 inhabitants. Malignant Pleural Mesothelioma (MPM) is the most common form of mesothelioma, accounting for approximately 80% of disease. Although rare in the global population, mesothelioma is linked to industrial pollutants and mineral fiber exposure, with approximately 80% of cases linked to asbestos. Due to the persistent asbestos exposure in many countries, a worldwide progressive increase in MPM incidence is expected for the current and coming years. The tumor grows in a loco-regional pattern, spreading from the parietal to the visceral pleura and invading the surrounding structures that induce the clinical picture of pleural effusion, pain and dyspnea. Distant spreading and metastasis are rarely observed, and most patients die from the burden of the primary tumor. Currently, there are no effective treatments for MPM, and the prognosis is invariably poor. Some studies average the prognosis to be roughly one-year after diagnosis. The uniquely poor mutational landscape which characterizes MPM appears to derive from a selective pressure operated by the environment; thus, inflammation and immune response emerge as key players in driving MPM progression and represent promising therapeutic targets. Here we recapitulate current knowledge on MPM with focus on the emerging network between genetic asset and inflammatory microenvironment which characterize the disease as amenable target for novel therapeutic approaches.<\/jats:p>","DOI":"10.3390\/cancers12051186","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T03:45:20Z","timestamp":1588909520000},"page":"1186","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge"],"prefix":"10.3390","volume":"12","author":[{"given":"David Michael","family":"Abbott","sequence":"first","affiliation":[{"name":"Department of Medical Sciences and Infective Diseases, Unit of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation and University of Pavia Medical School, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9193-9309","authenticated-orcid":false,"given":"Chandra","family":"Bortolotto","sequence":"additional","affiliation":[{"name":"Unit of Radiology, Department of Intensive Medicine, IRCCS Policlinico San Matteo Foundation and University of Pavia Medical School, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Benvenuti","sequence":"additional","affiliation":[{"name":"Candiolo Cancer Institute, FPO\u2014IRCCS\u2014Str. Prov.le 142, km. 3,95\u201410060 Candiolo (TO), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6106-7725","authenticated-orcid":false,"given":"Andrea","family":"Lancia","sequence":"additional","affiliation":[{"name":"Unit of Radiation Therapy, Department of Medical Sciences and Infective Diseases, IRCCS Policlinico San Matteo Foundation and University of Pavia Medical School, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7159-7869","authenticated-orcid":false,"given":"Andrea Riccardo","family":"Filippi","sequence":"additional","affiliation":[{"name":"Unit of Radiation Therapy, Department of Medical Sciences and Infective Diseases, IRCCS Policlinico San Matteo Foundation and University of Pavia Medical School, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0929-4394","authenticated-orcid":false,"given":"Giulia Maria","family":"Stella","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Infective Diseases, Unit of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation and University of Pavia Medical School, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,7]]},"reference":[{"key":"ref_1","first-page":"491","article-title":"Malignant pleural mesothelioma: An epidemiological perspective","volume":"1","author":"Robinson","year":"2012","journal-title":"Ann. Cardiothorac. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0041-3879(35)80795-2","article-title":"Roodhouse. Two Cases of Squamous Carcinoma of the Lung Occurring in Asbestosis","volume":"17","author":"Gloyne","year":"1935","journal-title":"Tubercle"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/oemed-2015-103074","article-title":"Pleural mesothelioma and lung cancer risks in relation to occupational history and asbestos lung burden","volume":"73","author":"Gilham","year":"2016","journal-title":"Occup. Environ. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/ajim.10047","article-title":"Malignant mesothelioma in Australia, 1945\u20132000","volume":"41","author":"Leigh","year":"2002","journal-title":"Am. J. Ind. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1183\/09059180.00007014","article-title":"Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic","volume":"24","author":"Stella","year":"2015","journal-title":"Eur. Respir. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","article-title":"Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.5858\/arpa.2017-0365-RA","article-title":"Malignant Mesothelioma and Its Non-Asbestos Causes","volume":"142","author":"Attanoos","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2471\/BLT.11.086678","article-title":"Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008","volume":"89","author":"Delgermaa","year":"2011","journal-title":"Bull. World Health Organ."},{"key":"ref_10","unstructured":"(2012). IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Arsenic, metals, fibres, and dusts. IARC Monogr. Eval. Carcinog. Risks Hum., 100, 11\u2013465."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.envint.2014.10.016","article-title":"Impact of an asbestos cement factory on mesothelioma incidence: global assessment of effects of occupational, familial, and environmental exposure","volume":"74","author":"Mensi","year":"2015","journal-title":"Environ. Int."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ngamwong, Y., Tangamornsuksan, W., Lohitnavy, O., Chaiyakunapruk, N., Scholfield, C.N., Reisfeld, B., and Lohitnavy, M. (2015). Additive Synergism between Asbestos and Smoking in Lung Cancer Risk: A Systematic Review and Meta-Analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0135798"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"13618","DOI":"10.1073\/pnas.1105887108","article-title":"Erionite exposure in North Dakota and Turkish villages with mesothelioma","volume":"108","author":"Carbone","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/00039890009604036","article-title":"Unusually high incidence of malignant pleural mesothelioma in a town of eastern Sicily: An epidemiological and environmental study","volume":"55","author":"Paoletti","year":"2000","journal-title":"Arch. Environ. Health"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3200\/AEOH.58.4.229-232","article-title":"Pleural mesothelioma cases in Biancavilla are related to a new fluoro-edenite fibrous amphibole","volume":"58","author":"Comba","year":"2003","journal-title":"Arch. Environ. Health"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1116\/1.3582324","article-title":"Carbon nanotubes and pleural damage: Perspectives of nanosafety in the light of asbestos experience","volume":"6","author":"Stella","year":"2011","journal-title":"Biointerphases"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/cam4.656","article-title":"Radiation-induced mesothelioma among long-term solid cancer survivors: A longitudinal analysis of SEER database","volume":"5","author":"Farioli","year":"2016","journal-title":"Cancer Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1440-1843.2005.00694.x","article-title":"Pathogenesis of malignant pleural mesothelioma","volume":"10","author":"Jaurand","year":"2005","journal-title":"Respirology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00432-008-0444-9","article-title":"Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors","volume":"135","author":"Weiner","year":"2009","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1097\/00000478-200308000-00001","article-title":"The immunohistochemical diagnosis of mesothelioma: A comparative study of epithelioid mesothelioma and lung adenocarcinoma","volume":"27","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.5858\/2008-132-397-AOITTD","article-title":"Application of Immunohistochemistry to the Diagnosis of Malignant Mesothelioma","volume":"132","author":"Marchevsky","year":"2008","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ctrv.2015.05.001","article-title":"The established and future biomarkers of malignant pleural mesothelioma","volume":"41","author":"Panou","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.prp.2016.07.010","article-title":"Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach","volume":"212","author":"Ascoli","year":"2016","journal-title":"Pathol. Res. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.humpath.2017.07.015","article-title":"The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell\/pleomorphic (sarcomatoid) carcinomas of the lung: Evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center","volume":"67","author":"Marchevsky","year":"2017","journal-title":"Hum. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41379-019-0320-y","article-title":"Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas","volume":"33","author":"Dacic","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jtho.2018.04.023","article-title":"New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center","volume":"13","author":"Nicholson","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Galateau Salle, F., Le Stang, N., Tirode, F., Courtiol, P., Nicholson, A.G., Tsao, M.S., Tazelaar, H.D., Churg, A., Dacic, S., and Roggli, V. (2020). Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center. J. Thorac. Oncol.","DOI":"10.1016\/j.jtho.2020.01.025"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Singh, A.S., Heery, R., and Gray, S.G. (2018). In Silico and In Vitro Analyses of LncRNAs as Potential Regulators in the Transition from the Epithelioid to Sarcomatoid Histotype of Malignant Pleural Mesothelioma (MPM). Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19051297"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","article-title":"Molecular classification of malignant pleural mesothelioma: Identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition","volume":"20","author":"Jaurand","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Turini, S., Bergandi, L., Gazzano, E., Prato, M., and Aldieri, E. (2019). Epithelial to Mesenchymal Transition in Human Mesothelial Cells Exposed to Asbestos Fibers: Role of TGF-\u03b2 as Mediator of Malignant Mesothelioma Development or Metastasis via EMT Event. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20010150"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/carcin\/bgy018","article-title":"FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase\/MMP1 signal","volume":"39","author":"Schelch","year":"2018","journal-title":"Carcinogenesis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ejcts.2009.08.027","article-title":"Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma","volume":"37","author":"Schramm","year":"2010","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1093\/jnci\/91.21.1820","article-title":"PTEN gene and integrin signaling in cancer","volume":"91","author":"Tamura","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.7314\/APJCP.2013.14.6.3625","article-title":"Hydrogen peroxide promotes epithelial to mesenchymal transition and stemness in human malignant mesothelioma cells","volume":"14","author":"Kim","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12943-017-0633-8","article-title":"Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells","volume":"16","author":"He","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"36256","DOI":"10.18632\/oncotarget.26332","article-title":"Calretinin promotes invasiveness and EMT in malignant mesothelioma cells involving the activation of the FAK signaling pathway","volume":"9","author":"Blum","year":"2018","journal-title":"Oncotarget"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Blum, W., Pecze, L., Rodriguez, J.W., Steinauer, M., and Schwaller, B. (2018). Regulation of calretinin in malignant mesothelioma is mediated by septin 7 binding to the CALB2 promoter. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4385-7"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"W\u00f6rthm\u00fcller, J., Salicio, V., Oberson, A., Blum, W., and Schwaller, B. (2019). Modulation of Calretinin Expression in Human Mesothelioma Cells Reveals the Implication of the FAK and Wnt Signaling Pathways in Conferring Chemoresistance towards Cisplatin. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215391"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/JTO.0000000000000466","article-title":"Recent insights emerging from malignant mesothelioma genome sequencing","volume":"10","author":"Carbone","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e1278330","DOI":"10.1080\/2162402X.2016.1278330","article-title":"Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma","volume":"6","author":"Kiyotani","year":"2017","journal-title":"OncoImmunology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2014","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/bjc.2013.130","article-title":"Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma","volume":"108","author":"Mezzapelle","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.tranon.2018.01.005","article-title":"Mutational Profiling of Malignant Mesothelioma Revealed Potential Therapeutic Targets in EGFR and NRAS","volume":"11","author":"Kim","year":"2018","journal-title":"Transl. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"8321","DOI":"10.18632\/oncotarget.7032","article-title":"Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas","volume":"7","author":"Kang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/jim-2017-000628","article-title":"Biological responses to asbestos inhalation and pathogenesis of asbestos-related benign and malignant disease","volume":"66","author":"Solbes","year":"2018","journal-title":"J. Investig. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1289\/ehp.9425","article-title":"New insight into intrachromosomal deletions induced by chrysotile in the gpt delta transgenic mutation assay","volume":"115","author":"Xu","year":"2007","journal-title":"Environ. Health Perspect."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.lungcan.2008.08.014","article-title":"Functional inactivation of NF2\/merlin in human mesothelioma","volume":"64","author":"Thurneysen","year":"2009","journal-title":"Lung Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M","article-title":"Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: Evidence for a two-hit mechanism of NF2 inactivation","volume":"24","author":"Cheng","year":"1999","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Felley-Bosco, E. (2018). Special Issue on Mechanisms of Mesothelioma Heterogeneity: Highlights and Open Questions. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113560"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Sekido, Y. (2018). Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma. Cancers (Basel), 10.","DOI":"10.3390\/cancers10040090"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"13432","DOI":"10.1073\/pnas.1612074113","article-title":"High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma","volume":"113","author":"Yoshikawa","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/470476a","article-title":"Cancer: When catastrophe strikes a cell","volume":"470","author":"Tubio","year":"2011","journal-title":"Nature"},{"key":"ref_55","first-page":"1227","article-title":"Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer","volume":"55","author":"Sekido","year":"1995","journal-title":"Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/s13046-019-1352-3","article-title":"Dropwort-induced metabolic reprogramming restrains YAP\/TAZ\/TEAD oncogenic axis in mesothelioma","volume":"38","author":"Pulito","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/jnci\/djy171","article-title":"Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide","volume":"110","author":"Walpole","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"270","DOI":"10.21037\/tlcr.2017.05.03","article-title":"BAP1, a tumor suppressor gene driving malignant mesothelioma","volume":"6","author":"Cheung","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Pignochino, Y., Dell\u2019Aglio, C., Inghilleri, S., Zorzetto, M., Basiric\u00f2, M., Capozzi, F., Canta, M., Piloni, D., Cemmi, F., and Sangiolo, D. (2015). The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1363-1"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/JTO.0000000000000055","article-title":"PI3K\/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy","volume":"9","author":"Bitanihirwe","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"32992","DOI":"10.1038\/srep32992","article-title":"PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma","volume":"6","author":"Kanteti","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.anndiagpath.2016.04.007","article-title":"c-Met expression and MET amplification in malignant pleural mesothelioma","volume":"23","author":"Bois","year":"2016","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"113673","DOI":"10.18632\/oncotarget.22817","article-title":"Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma","volume":"8","author":"Hylebos","year":"2017","journal-title":"Oncotarget"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1158\/0008-5472.CAN-18-4093","article-title":"Inactivation of Bap1 Cooperates with Losses of Nf2 and Cdkn2a to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models","volume":"79","author":"Kukuyan","year":"2019","journal-title":"Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jtho.2016.05.020","article-title":"The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing","volume":"11","author":"Hylebos","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1073\/pnas.0712399105","article-title":"Transcriptome sequencing of malignant pleural mesothelioma tumors","volume":"105","author":"Dong","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Dong, L., Jensen, R.V., De Rienzo, A., Gordon, G.J., Xu, Y., Sugarbaker, D.J., and Bueno, R. (2009). Differentially expressed alternatively spliced genes in malignant pleural mesothelioma identified using massively parallel transcriptome sequencing. BMC Med. Genet., 10.","DOI":"10.1186\/1471-2350-10-149"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1349-7006.2006.00386.x","article-title":"Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32","volume":"98","author":"Taniguchi","year":"2007","journal-title":"Cancer Sci."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Sage, A.P., Martinez, V., Minatel, B., Pewarchuk, M., Marshall, E.A., Macaulay, G.M., Hubaux, R., Pearson, D.D., Goodarzi, A.A., and Dellaire, G. (2018). Genomics and Epigenetics of Malignant Mesothelioma. High Throughput, 7.","DOI":"10.3390\/ht7030020"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1610322","DOI":"10.1080\/23723556.2019.1610322","article-title":"Unraveling the cellular heterogeneity of malignant pleural mesothelioma through a deconvolution approach","volume":"6","author":"Blum","year":"2019","journal-title":"Mol. Cell. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fphar.2015.00113","article-title":"Mesothelial cells in tissue repair and fibrosis","volume":"6","author":"Mutsaers","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Rouka, E., Beltsios, E., Goundaroulis, D., Vavougios, G.D., Solenov, E., Hatzoglou, C., Gourgoulianis, K.I., and Zarogiannis, S.G. (2019). In Silico Transcriptomic Analysis of Wound-Healing-Associated Genes in Malignant Pleural Mesothelioma. Medicina (Kaunas), 55.","DOI":"10.3390\/medicina55060267"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative Molecular Characterization of Malignant Pleural Mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.humpath.2010.03.002","article-title":"Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter","volume":"41","author":"Tan","year":"2010","journal-title":"Hum. Pathol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/imr.12525","article-title":"Immunoregulatory functions of VISTA","volume":"276","author":"Nowak","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ebiom.2019.09.003","article-title":"Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions","volume":"48","author":"Alcala","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"16848","DOI":"10.18632\/oncotarget.4253","article-title":"Reactive oxygen species a double-edged sword for mesothelioma","volume":"6","author":"Benedetti","year":"2015","journal-title":"Oncotarget"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1158\/0008-5472.CAN-06-3123","article-title":"Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1","volume":"67","author":"Valinluck","year":"2007","journal-title":"Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"16223","DOI":"10.1074\/jbc.M113.527424","article-title":"Poly(ADP-ribose) polymerase 1 (PARP1) associates with E3 ubiquitin-protein ligase UHRF1 and modulates UHRF1 biological functions","volume":"289","author":"Wolf","year":"2014","journal-title":"J. Boil. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Zampieri, M., Passananti, C., Calabrese, R., Perilli, M., Corbi, N., De Cave, F., Guastafierro, T., Bacalini, M.G., Reale, A., and Amicosante, G. (2009). Parp1 Localizes within the Dnmt1 Promoter and Protects Its Unmethylated State by Its Enzymatic Activity. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0004717"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3389\/fonc.2019.01293","article-title":"Epigenetic Regulation of miRNA Expression in Malignant Mesothelioma: miRNAs as Biomarkers of Early Diagnosis and Therapy","volume":"9","author":"Tomasetti","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Weber, D.G., Johnen, G., Bryk, O., Jockel, K.-H., and Br\u00fcning, T. (2012). Identification of miRNA-103 in the cellular fraction of human peripheral blood as a potential biomarker for malignant mesothelioma--a pilot study. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0030221"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/JTO.0b013e3182572e83","article-title":"Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma","volume":"7","author":"Kirschner","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1002\/jcb.27586","article-title":"Clinical significance of serum DRAM1 mRNA, ARSA mRNA, hsa-miR-2053 and lncRNA-RP1-86D1.3 axis expression in malignant pleural mesothelioma","volume":"120","author":"Matboli","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3389\/fonc.2020.00445","article-title":"Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation","volume":"10","author":"Ferrari","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-069X-7-4","article-title":"Translocation pathways for inhaled asbestos fibers","volume":"7","author":"Miserocchi","year":"2008","journal-title":"Environ. Health"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1525-1578(10)60639-3","article-title":"Severe chromosomal aberrations in pleural mesotheliomas with unusual mesodermal features. Comparative genomic hybridization evidence for a mesothelioma subgroup","volume":"2","author":"Krismann","year":"2000","journal-title":"J. Mol. Diagn."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1136\/jcp.2005.026435","article-title":"Comparative genomic hybridisation in malignant deciduoid mesothelioma","volume":"59","author":"Scattone","year":"2006","journal-title":"J. Clin. Pathol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.jtho.2018.07.015","article-title":"Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma","volume":"13","author":"Arulananda","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mrfmmm.2011.01.001","article-title":"XRCC1 and ERCC1 variants modify malignant mesothelioma risk: A case-control study","volume":"708","author":"Betti","year":"2011","journal-title":"Mutat. Res. Mol. Mech. Mutagen."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.mrfmmm.2006.02.005","article-title":"Polymorphisms in DNA repair genes as risk factors for asbestos-related malignant mesothelioma in a general population study","volume":"599","author":"Dianzani","year":"2006","journal-title":"Mutat. Res. Mol. Mech. Mutagen."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1749-6632.2010.05554.x","article-title":"Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model","volume":"1203","author":"Hillegass","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1158\/0008-5472.CAN-11-3481","article-title":"Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma","volume":"72","author":"Jube","year":"2012","journal-title":"Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imr.12601","article-title":"High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair","volume":"280","author":"Bianchi","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Mukherjee, A., and Vasquez, K.M. (2020). Targeting chromosomal architectural HMGB proteins could be the next frontier in cancer therapy Cancer Res. Cancer Res.","DOI":"10.1158\/0008-5472.CAN-19-3066"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"12611","DOI":"10.1073\/pnas.1006542107","article-title":"Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation","volume":"107","author":"Yang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.ajpath.2013.07.029","article-title":"Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-\u03b1 signaling","volume":"183","author":"Qi","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-15-1130","article-title":"HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients. Version 2","volume":"22","author":"Napolitano","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Tabata, C., Shibata, E., Tabata, R., Kanemura, S., Mikami, K., Nogi, Y., Masachika, E., Nishizaki, T., and Nakano, T. (2013). Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-205"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e1786","DOI":"10.1038\/cddis.2015.153","article-title":"Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression","volume":"6","author":"Yang","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_102","first-page":"4183157","article-title":"HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma","volume":"2019","author":"Wang","year":"2019","journal-title":"Dis. Markers"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Minnema-Luiting, J., Vroman, H., Aerts, J., and Cornelissen, R. (2018). Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19041041"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Cornelissen, R., Lievense, L.A., Maat, A.P., Hendriks, R.W., Hoogsteden, H.C., Bogers, A.J., Hegmans, J.P., and Aerts, J.G. (2014). Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0106742"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1002\/cncr.26143","article-title":"Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma","volume":"117","author":"Burt","year":"2011","journal-title":"Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00262-011-1073-8","article-title":"Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients","volume":"60","author":"Suzuki","year":"2011","journal-title":"Cancer Immunol. Immunother"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e1261241","DOI":"10.1080\/2162402X.2016.1261241","article-title":"Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma","volume":"6","author":"Marcq","year":"2016","journal-title":"OncoImmunology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2013.12.005","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Nishikawa","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.jtho.2016.07.033","article-title":"Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab","volume":"11","author":"Khanna","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/2326-6066.CIR-16-0171","article-title":"Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors","volume":"4","author":"Awad","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e1638211","DOI":"10.1080\/2162402X.2019.1638211","article-title":"Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes","volume":"8","author":"Klampatsa","year":"2019","journal-title":"OncoImmunology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11864-019-0613-x","article-title":"Use of Immune Checkpoint Inhibitors in Mesothelioma","volume":"20","author":"Forde","year":"2019","journal-title":"Curr. Treat. Opt. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1172\/JCI80005","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment: Expect the unexpected","volume":"125","author":"Marvel","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"S353","DOI":"10.21037\/jtd.2017.10.132","article-title":"Serum mesothelin and other biomarkers: what have we learned in the last decade?","volume":"10","author":"Cristaudo","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","article-title":"Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma","volume":"69","author":"Creaney","year":"2014","journal-title":"Thorax"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/bjc.2017.22","article-title":"Prognostication and monitoring of mesothelioma using biomarkers: a systematic review","volume":"116","author":"Arnold","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Ostroff, R., Mehan, M.R., Stewart, A., Ayers, D., Brody, E.N., Williams, S.A., Levin, S., Black, B., Harbut, M., and Carbone, M. (2012). Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046091"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.18632\/oncotarget.14712","article-title":"Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis.Oncotarget","volume":"8","author":"Pei","year":"2017","journal-title":"Oncotarget"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.5301\/jbm.5000229","article-title":"Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma","volume":"32","author":"Bonotti","year":"2017","journal-title":"Int. J. Boil. Markers"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12943-018-0891-0","article-title":"Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis","volume":"17","author":"Smeele","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.acra.2017.03.006","article-title":"Can CT and MR Shape and Textural Features Differentiate Benign Versus Malignant Pleural Lesions?","volume":"24","author":"Pena","year":"2017","journal-title":"Acad. Radiol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000503239","article-title":"Diagnostic Value of Computed Tomography Imaging Features in Malignant Pleural Mesothelioma","volume":"99","author":"Fortin","year":"2019","journal-title":"Respiration"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/RCT.0000000000000727","article-title":"Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography?","volume":"42","author":"Escalon","year":"2018","journal-title":"J. Comput. Assist. Tomogr."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2214\/ajr.159.5.1414807","article-title":"Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability","volume":"159","author":"Patz","year":"1992","journal-title":"Am. J. Roentgenol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3348\/kjr.2016.17.4.545","article-title":"Multidetector CT Findings and Differential Diagnoses of Malignant Pleural Mesothelioma and Metastatic Pleural Diseases in Korea","volume":"17","author":"Kim","year":"2016","journal-title":"Korean J. Radiol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1148\/rg.346130089","article-title":"Multimodality imaging for characterization, classification, and staging of malignant pleural mesothelioma","volume":"34","author":"Nickell","year":"2014","journal-title":"Radiographics"},{"key":"ref_129","first-page":"134","article-title":"Diagnostic Imaging and workup of Malignant Pleural Mesothelioma","volume":"88","author":"Cardinale","year":"2017","journal-title":"Acta. Biomed."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1148\/rg.241035058","article-title":"Malignant Pleural Mesothelioma: Evaluation with CT, MR Imaging, and PET","volume":"24","author":"Wang","year":"2004","journal-title":"RadioGraphics"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5812\/iranjradiol.8764","article-title":"Thoracic computed tomography findings in malignant mesothelioma","volume":"9","author":"Salk","year":"2012","journal-title":"Iran. J. Radiol."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Xu, L.L., Yang, Y., Wang, Z., Wang, X.J., Tong, Z.H., and Shi, H.Z. (2018). Malignant pleural mesothelioma: Diagnostic value of medical thoracoscopy and long-term prognostic analysis. BMC Pulm. Med., 18.","DOI":"10.1186\/s12890-018-0619-3"},{"key":"ref_133","first-page":"E254","article-title":"Guidelines for the diagnosis and treatment of malignant pleural mesothelioma","volume":"5","author":"Clarke","year":"2013","journal-title":"J. Thorac. Dis."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"85","DOI":"10.21037\/jovs.2017.05.05","article-title":"Video assisted thoracoscopic and open chest surgery in diagnosis and treatment of malignant pleural diseases","volume":"3","author":"Perikleous","year":"2017","journal-title":"J. Vis. Surg."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Xia, H., Wang, X.-J., Zhou, Q., Shi, H.Z., and Tong, Z.H. (2014). Efficacy and safety of talc pleurodesis for malignant pleural effusion: a meta-analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087060"},{"key":"ref_136","first-page":"CD010529","article-title":"Interventions for the management of malignant pleural effusions: a network meta-analysis","volume":"2016","author":"Clive","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.lungcan.2019.09.003","article-title":"Survival in patients with malignant pleural effusion undergoing talc pleurodesis","volume":"137","author":"Hassan","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"French Cooperative ThoracicIntergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref_141","unstructured":"NCCN Clinical Practice Guidelines in Oncology (2020, April 20). MalignantPleural Mesothelioma. Available online: www.nccn.org\/professionals\/physician_gls\/default.aspx."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S0140-6736(14)60418-9","article-title":"MesoVATS Collaborators Efficacy and Cost of Video-Assisted Thoracoscopic Partial Pleurectomy versus Talc Pleurodesis in Patients with Malignant Pleural Mesothelioma (MesoVATS): An Open-Label, Randomised, Controlled Trial","volume":"384","author":"Ritchie","year":"2014","journal-title":"Lancet"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Cancer and Leukemia Group B (CALGB 30101). Gefitinib in patients with malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1593\/neo.101156","article-title":"Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma","volume":"13","author":"Ou","year":"2011","journal-title":"Neoplasia"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.21037\/tlcr.2019.11.23","article-title":"Immunotherapy for mesothelioma: A critical review of current clinical trials and future perspectives","volume":"9","author":"Gray","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial [published correction appears in Lancet Oncol. 2019 Mar;20,e132]","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e1082028","DOI":"10.1080\/2162402X.2015.1082028","article-title":"Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomes","volume":"5","author":"Cornwall","year":"2015","journal-title":"OncoImmunology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.3389\/fimmu.2018.02034","article-title":"Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS","volume":"9","author":"Klaver","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"280","DOI":"10.21037\/tlcr.2019.05.05","article-title":"Aerts JGJV. A multicenter, randomized, phase II\/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial","volume":"8","author":"Belderbos","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2017.04.004","article-title":"CAR T-cell therapy for lung cancer and malignant pleural mesothelioma","volume":"187","author":"Zeltsman","year":"2017","journal-title":"Transl. Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e1363137","DOI":"10.1080\/2162402X.2017.1363137","article-title":"CAR T-cell immunotherapy of MET-expressing malignant mesothelioma","volume":"6","author":"Thayaparan","year":"2017","journal-title":"OncoImmunology"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.stem.2018.01.016","article-title":"Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo","volume":"22","author":"Kooreman","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"350","DOI":"10.21037\/tlcr.2017.06.06","article-title":"Targeting the epigenome in malignant pleural mesothelioma","volume":"6","author":"McLoughlin","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/JTO.0b013e318191520c","article-title":"Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma","volume":"4","author":"Ramalingam","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaoncol.2016.3049","article-title":"Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial","volume":"3","author":"Szlosarek","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/(SICI)1097-0142(19980415)82:8<1578::AID-CNCR21>3.0.CO;2-0","article-title":"Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B","volume":"82","author":"Samuels","year":"1998","journal-title":"Cancer"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/JTO.0b013e318168da0a","article-title":"Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: Results of cancer and leukemia group B 159904","volume":"3","author":"Kratzke","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin Immunotherapy for Cancer: Ready for Prime Time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J Clin Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.bbrc.2018.08.193","article-title":"Targeting CD26 suppresses proliferation of malignant mesothelioma cell via downmodulation of ubiquitin-specific protease 22","volume":"504","author":"Okamoto","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.canlet.2016.10.020","article-title":"Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP\/CD44 growth stimulatory axis","volume":"385","author":"Tanaka","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"101986982","DOI":"10.1155\/2018\/1986982","article-title":"Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53","volume":"2018","author":"Walter","year":"2018","journal-title":"J. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1158\/1535-7163.MCT-16-0821","article-title":"Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis","volume":"16","author":"Cooper","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/1535-7163.MCT-13-0918","article-title":"Identification, mechanism of action, and antitumor activity of a small molecule inhibitor of hippo, TGF-\u03b2, and Wnt signaling pathways","volume":"13","author":"Basu","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40880-016-0123-1","article-title":"Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics","volume":"35","author":"Nerini","year":"2016","journal-title":"Chin. J. Cancer"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"39284","DOI":"10.1038\/srep39284","article-title":"Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging","volume":"6","author":"Giordano","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"37027","DOI":"10.1038\/srep37027","article-title":"3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors","volume":"6","author":"Giordano","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2147\/IJN.S186344","article-title":"Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: An in vitro study","volume":"14","author":"Cova","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_172","first-page":"PA1590","article-title":"Novel therapeutic strategies against malignant pleural mesothelioma by selumetinib-loaded targeted nanoparticles","volume":"50","author":"Stella","year":"2017","journal-title":"Eur. Resp. J."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/modpathol.2010.134","article-title":"Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium","volume":"23","author":"Sato","year":"2010","journal-title":"Mod. Pathol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3389\/fonc.2019.01366","article-title":"The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy","volume":"9","author":"Chu","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2005.07.010","article-title":"Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM)","volume":"51","author":"Klabatsa","year":"2006","journal-title":"Lung Cancer"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lungcan.2015.07.015","article-title":"Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT","volume":"90","author":"Francis","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc704","article-title":"Hypoxia\u2014a key regulatory factor in tumour growth","volume":"2","author":"Harris","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Kim, M.C., Hwang, S.H., Kim, N.Y., Lee, H.S., Ji, S., Yang, Y., and Kim, Y. (2018). Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4720-z"},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Ullmann, P., Nurmik, M., Begaj, R., Haan, S., and Letellier, E. (2019). Hypoxia-and MicroRNA-Induced Metabolic Reprogramming of Tumor-Initiating Cells. Cells, 8.","DOI":"10.3390\/cells8060528"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/s41598-017-02694-0","article-title":"Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism","volume":"7","author":"Melaiu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.ymthe.2019.05.017","article-title":"Hypoxia Induces Drug Resistance in Colorectal Cancer through the HIF-1\u03b1\/miR-338-5p\/IL-6 Feedback Loop","volume":"27","author":"Xu","year":"2019","journal-title":"Mol. Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/5\/1186\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:26:34Z","timestamp":1760174794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/5\/1186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,7]]},"references-count":181,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["cancers12051186"],"URL":"https:\/\/doi.org\/10.3390\/cancers12051186","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,7]]}}}